ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $104 | +60.0% | 9,126 | +44.3% | 0.00% | – |
| Q2 2023 | $65 | -30.1% | 6,325 | -47.6% | 0.00% | – |
| Q1 2023 | $93 | +106.7% | 12,079 | +98.7% | 0.00% | – |
| Q4 2022 | $45 | -99.1% | 6,080 | +818.4% | 0.00% | – |
| Q3 2022 | $5,000 | -28.6% | 662 | -15.5% | 0.00% | – |
| Q2 2022 | $7,000 | -58.8% | 783 | -58.5% | 0.00% | – |
| Q1 2022 | $17,000 | -95.7% | 1,886 | -93.3% | 0.00% | – |
| Q4 2021 | $392,000 | +668.6% | 28,196 | +494.0% | 0.00% | – |
| Q3 2021 | $51,000 | +292.3% | 4,747 | +223.1% | 0.00% | – |
| Q2 2021 | $13,000 | -91.3% | 1,469 | -89.6% | 0.00% | – |
| Q1 2021 | $150,000 | +500.0% | 14,105 | +405.0% | 0.00% | – |
| Q3 2020 | $25,000 | – | 2,793 | +139550.0% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 2 | -98.5% | 0.00% | – |
| Q1 2018 | $1,000 | – | 134 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |